EZH2 and Burkitt lymphoma: In conclusion, our study demonstrated that combining dEZH2 and aPD1 in Burkitt’s lymphoma counteracted immune evasion caused by EZH2 inhibition-induced PD-L1 upregulation, leading to significantly enhanced apoptosis both in vitro and in vivo (Figure 6).